# First-in-Human Study of TAK-280 in Participants With Solid Tumors

> **NCT05220098** · PHASE1,PHASE2 · TERMINATED · sponsor: **Takeda** · enrollment: 69 (actual)

## Conditions studied

- Unresectable Locally Advanced or Metastatic Cancer

## Interventions

- **DRUG:** TAK-280

## Key facts

- **NCT ID:** NCT05220098
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-22
- **Primary completion:** 2025-07-28
- **Final completion:** 2025-07-28
- **Target enrollment:** 69 (ACTUAL)
- **Why stopped:** Terminated due to limited anti-cancer activity
- **Last updated:** 2025-08-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05220098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05220098, "First-in-Human Study of TAK-280 in Participants With Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05220098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*